William Blair & Company’s Pacira BioSciences PCRX Stock Holding History

William Blair & Company’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-450	Closed	-$27K	–	1974
2021 Q4	$27K	Hold	450	–	–	﹤0.01%	1831
2021 Q3	$25K	Hold	450	–	–	﹤0.01%	1756
2021 Q2	$27K	Sell	450 -20	-4%	-$1.27K	﹤0.01%	1757
2021 Q1	$33K	Hold	470	–	–	﹤0.01%	1706
2020 Q4	$28K	Sell	470 -7	-1%	-$410	﹤0.01%	1677
2020 Q3	$29K	Buy	477 +27	+6%	+$1.57K	﹤0.01%	1553
2020 Q2	$24K	Hold	450	–	–	﹤0.01%	1518
2020 Q1	$15K	Hold	450	–	–	﹤0.01%	1529
2019 Q4	$20K	Buy	+450	New	+$19.1K	﹤0.01%	1584

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

William Blair & Company's PCRX Position: Q1 2022 in Review

William Blair & Company sold out of Pacira BioSciences (PCRX) in Q1 2022, closing a stake of 450 shares — an estimated $27K sold.

William Blair & Company first reported a position in PCRX in Q4 2019 and held it in 9 quarters. The position peaked at $33K in Q1 2021. 301 funds tracked by Wall St. Rank hold PCRX as of Q1 2022.

William Blair & Company reported no remaining Pacira BioSciences position as of Q1 2022 after selling out during the quarter.
William Blair & Company sold 450 Pacira BioSciences shares in Q1 2022, an estimated $27K.
William Blair & Company first reported a position in Pacira BioSciences in Q4 2019 and held it in 9 quarters.
William Blair & Company's Pacira BioSciences position peaked at $33K in Q1 2021.
301 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2022.

Based on William Blair & Company's 13F filing for Q1 2022, filed 13 May 2022.